Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.
Nocion Therapeutics has raised $62.0M in total funding. The most recent round was Series B. The last funding was announced in March 2024.
Nocion Therapeutics's investors include Mission BioCapital, OUP (Osage University Partners), Canaan Partners, F-Prime Capital, Arkin Holdings.
Nocion Therapeutics is headquartered in Cambridge, United States.
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.
Nocion Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nocion Therapeutics — Funding & Investors." VCBacked, March 4, 2024, https://www.vcbacked.co/company/nocion-therapeutics. Accessed October 29, 2026.
VCBacked. (2024). Nocion Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/nocion-therapeutics
{{cite web |title=Nocion Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nocion-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated